Bristol-Myers Must Face Trimmed $6.7B Celgene Investor Suit
By Lauren Berg · December 1, 2025, 11:36 PM EST
A Manhattan federal judge Monday trimmed UMB Bank's lawsuit accusing Bristol-Myers Squibb of slow-walking the U.S. Food and Drug Administration approval process for three drugs to avoid paying shareholders $6.7 billion...
To view the full article, register now.